Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy
PHASE1CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
Not specified
Study Completion Date
April 30, 1990
Conditions
HIV Infections
Interventions
DRUG
Zidovudine
DRUG
Aldesleukin
Trial Locations (1)
94305
Stanford Univ School of Medicine, Stanford
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000728 - Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy | Biotech Hunter | Biotech Hunter